CSL宣布完成对诺华全球流感疫苗业务的收购

rojjer

8月3日，生物技术巨头公司CSL今日宣布，它已经正式完成了对诺华制药Novartis全球流感疫苗的收购。CSL表示使用现金来完成了此次收购案，CSL的子公司bioCSL已经成为世界第二大的流感疫苗制造公司，而流感疫苗行业在全球的市场规模为40亿澳元。上周五，该公司宣布收购案即将完成之后，公司的股价一睹飙升至最高每股99.9澳元。

早在2014年10月，澳大利亚疫苗公司CSL就计划以2.75亿美元（3.1224亿澳元）并购制药集团诺华（Novartis）旗下的全球流感疫苗业务部，进而将该部门与CSL的子公司bioCSL合并。CSL表示，bioCSL现有的流感疫苗业务与诺华该部门合并将能在价值40亿美元的全球流感疫苗产业中组建成全球第二大企业。CSL指出，该合并企业将在美国、英国、德国和澳大利亚等地建设制药厂，实现产品多样化，同时在各运营中心中拥有强有力的大流行前和流行性疾病疫苗经营特权。“业务合并将有着强劲的发展前景，有望在未来3到5年内实现年销售额近10亿美元的目标。”CSL称。CSL首席执行官（CEO）皮罗尔特（Paul Perreault）表示，诺华的流感疫苗部门将为bioCSL提供了国际领导者的地位，因为诺华对这个具有吸引力的行业已十分熟悉。“该业务部门将通过提供其一流的设备、全球范围的业务以及产品和地域多样性等因素来使bioCSL发生转型。CSL在所熟悉的领域上已展示了利用好专业制药企业收购的能力。该并购有可能为bioCSL创造一个全球性平台，在众多方面都能与我们的全球蛋白质科学业务部门相媲美。”

rojjer

Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million

Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed effective July 31, 2015 the divestiture of its influenza vaccine unit to CSL Limited.

This marks the end of a series of transactions previously announced and completed,that are focusing Novartis on its three leading businesses of global scale - pharmaceuticals, generics and eye care.

Since April 2014, the influenza vaccines unit results have been reported under Discontinuing Operations in the Novartis consolidated financial statements.

Disclaimer
Closing in certain jurisdictions is subject to statutory employee consultation. The foregoing release contains forward-looking statements that can be identified by words such as "pipeline," "are focusing," or similar terms, or by express or implied discussions regarding any potential strategic benefits, synergies or opportunities as a result of the announced transactions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Novartis will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the transactions. Neither can there be any guarantee that Novartis will achieve any particular financial results in the future. In particular, management's expectations could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing data, and unexpected safety data; unexpected regulatory actions or delays or government regulation generally; the potential that the strategic benefits, synergies or opportunities expected from the transactions may not be realized or may take longer to realize than expected; the Company's ability to obtain or maintain proprietary intellectual property protection; global trends toward health care cost containment, including ongoing pricing pressures; general economic and industry conditions, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.